Replies to post #439821 on NorthWest Biotherapeutics Inc (NWBO)

[dennisdave]

senti,

You are right that they will not remove IDH mutated from the data when comparing it to external trials for the reason you stated.

But I'm sure they will remove it to show how well the trial did without IDH mutated so that future medical trials now in phase 2, will be able to compare it with DCVAX L.

[newman2021]

makes sense! Thanks senti!

[hoffmann6383]

Is that true senti? I thought (or maybe hoped is the better word) that we had plenty of control arms from various tests out there that did separate. That is disappointing if there isn't a good control arm with this separated

If that is the case it sounds like the redefinition of GBM might have the effect of slightly lowering the potential market of dcvax-l and also not offering any improvement on the data (although there would be if we had a good contol arm). The benefit would be seen by the patient with the knowledge gained in what treatment(s) work for which patient.